Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Maartje S. Jacobs
Observed names:
Jacobs, Maartje S.,
M Jacobs,
M. S. Jacobs,
M.S. Jacobs,
Maartje Jacobs,
Maartje S Jacobs
show all 6
Institutions:
University of Groningen,
Sanofi (Netherlands),
Martini Ziekenhuis,
Deventer Ziekenhuis
Observed institutions:
University Medical Center Groningen,
University of Groningen,
Sanofi (Netherlands),
Martini Ziekenhuis,
Deventer Ziekenhuis,
Federatie van Nederlandse Trombosediensten
show all 6
ORCID:
0000-0002-6185-4718
Observed ORCID:
0000-0002-6185-4718
OpenAlex ID:
A5030724070
Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands
2016
·
Maartje S. Jacobs
, Femke Kaasenbrood
, et al.
·
EP Europace
·
109
PDF
Leveraging the Similarities Between Cost-Effectiveness Analysis and Value-Based Healthcare
2021
·
Jelle Walraven
, Maartje S. Jacobs
, et al.
·
Value in Health
·
40
Atrial Fibrillation in Africa—An Under-Reported and Unrecognized Risk Factor for Stroke: A Systematic Review
2019
·
Maartje S. Jacobs
, Marinus Van Hulst
, et al.
·
Global Heart
·
30
PDF
Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions
2019
·
M. S. Jacobs
, M. van Hulst
, et al.
·
Netherlands Heart Journal
·
29
PDF
Incidence, treatment and mortality of new-onset atrial fibrillation patients at the intensive care unit
2020
·
Maartje S Jacobs
, Bert Loef
, et al.
·
Open Heart
·
26
PDF
Secondary adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands
2018
·
Maartje S. Jacobs
, Jeroen F. Schouten
, et al.
·
Current Medical Research and Opinion
·
16
Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation
2017
·
Maartje S. Jacobs
, Lisa A. de Jong
, et al.
·
The European Journal of Health Economics
·
13
PDF
Health economic evaluation of nation-wide screening programmes for atrial fibrillation in the Netherlands
2022
·
Marinus van Hulst
, Robert G Tieleman
, et al.
·
European Heart Journal - Quality of Care and Clinical Outcomes
·
10
Optimal antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary intervention: triple therapy is too much!
2018
·
M. S. Jacobs
, R. G. Tieleman
·
Netherlands Heart Journal
·
8
PDF
Lean Body Mass and Total Body Weight Versus Body Surface Area as a Determinant of Docetaxel Pharmacokinetics and Toxicity
2022
·
Rien H. L. Hoge
, Suzan E. H. Detert Oude Weme
, et al.
·
Therapeutic Drug Monitoring
·
6
PDF
Perioperative bridging of vitamin K antagonist treatment in patients with atrial fibrillation: only a very small group of patients benefits
2018
·
Simon van der Pol
, Maartje S Jacobs
, et al.
·
EP Europace
·
6
The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands
2017
·
Marinus van Hulst
, Jelena Stevanovic
, et al.
·
Journal of Medical Economics
·
6
PDF
Letter responding to Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Societad Latinoamericana de Estimulation Cardiaca y Electrofisiologia (SOLAECE)
2018
·
Maartje S Jacobs
, Marinus van Hulst
, et al.
·
EP Europace
·
5
PDF
Screening for Atrial Fibrillation in Sub-Saharan Africa: A Health Economic Evaluation to Assess the Feasibility in Nigeria
2021
·
M. S. Jacobs
, A. M. Adeoye
, et al.
·
Global Heart
·
4
PDF
Predictors for total hospital and cardiology cost claims among patients with atrial fibrillation initiating dabigatran or acenocoumarol in The Netherlands
2017
·
M. S. Jacobs
, M. W. J. van Leent
, et al.
·
Journal of Medical Economics
·
3
PDF
Ready-to-use parenteral amiodarone: a feasibility study towards a long-term stable product formulation
2016
·
Maartje S Jacobs
, Marianne Luinstra
, et al.
·
European Journal of Hospital Pharmacy
·
2
PDF
Author's Reply
2022
·
Jelle Walraven
, Maartje S. Jacobs
, et al.
·
Value in Health
Anticoagulation in Atrial Fibrillation: Consideration for treatment and health economic aspects
2020
·
Maartje Jacobs
·
University of Groningen research database (University of Groningen / Centre for Information Technology)
PDF
1202The incidence, treatment and mortality of new-onset atrial fibrillation patients at the intensive care unit
2019
·
M Jacobs
, B G Loef
, et al.
·
European Heart Journal
Pcv135 - Non-vitamin K Antagonist Oral Anticoagulants Prescription Monitoring: How to Optimize Vigilance in Stroke Prevention
2018
·
M.S. Jacobs
, M. van Hulst
, et al.
·
Value in Health
Zero-residual syringe als verpakkingsmateriaal voor bevacizumab als intravitreale injectie - Antwoord van de auteurs
2017
·
Maartje S. Jacobs
, Wietske L. Hemminga
, et al.
·
Pharmaceutisch Weekblad
Abstract 11651: Cost-effectiveness of Screening for Atrial Fibrillation in Primary Care With a Hand-held, Single-lead ECG Device in the Netherlands
2016
·
Maartje Jacobs
, Femke Kaasenbrood
, et al.
·
Circulation
Kwalificatie van de zero-residual syringe (Zeringe) als verpakkingsmateriaal voor bevacizumab als intravitreale injectie
2016
·
Maartje S. Jacobs
, Wietske L. Hemminga
, et al.
·
Pharmaceutisch Weekblad
Show more works
View as search
Works count:
24
Citation count:
313
H-index:
8
I10-index:
8
Year
Topic
Type